According to Long and associates,1 ocular involvement is a rare complication in therapy with sulfonamide compounds. As far as could be determined, ocular complications, although they indicated the advisability of stopping the treatment, did not have the same mandatory importance as other complications, such as hepatitis, leukopenia with granulocytopenia, acute agranulocytosis and hemolytic anemia.
Nevertheless, the data found in the ophthalmologic literature and occasionally elsewhere regarding ocular involvement as a consequence of the use of sulfonamide compounds are numerous enough to suggest the necessity for a systematic study of the subject.
PENETRATION AND DISTRIBUTION OF SULFONAMIDE COMPOUNDS IN THE EYE
Sulfonamide compounds given orally reach the eye as soon as fifteen minutes after they are taken (Bellows and Chinn2) and arrive at their maximum concentration in the ocular tissues about the sixth hour. They are found in the tears (Venco3) and can still be traced in the
ALVARO ME. EFFECTS OTHER THAN ANTI-INFECTIOUS OF SULFONAMIDE COMPOUNDS ON EYE. Arch Ophthalmol. 1943;29(4):615–632. doi:10.1001/archopht.1943.00880160105008
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: